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Background: This study aims to investigate the leukogenic effect of astragalus polysaccharide (APS), to compare its
effect of increasing the numbers of mature granulocytes with that of granulocyte colony-stimulating factor (G-CSF),
and to investigate the mechanism.
Methods: Rats were arbitrarily grouped into four groups (control, cyclophosphamide (CTX), CTX + APS, and
CTX + G-CSF groups), and each group was then arbitrarily divided into five subgroups according to the time period
since CTX infusion (0, 4, 7, 10, and 14 days). The expression of leukocyte selectin (L-selectin), its ligand, and
shedding-related protease on granulocytes was analyzed. Leukocyte counts were obtained. Chemotactic capacity of
polymorphonuclear leukocytes (PMNLs) was assessed.
Results: Both APS and G-CSF restored the expression of L-selectin, P-selectin glycoprotein ligand-1 (PSGL-1),
CD11b/CD18, and ADAM17 to normal levels (P > 0.05 vs. control group on each time point), with APS eliciting a
greater effect than G-CSF (P = 0.005 on day 7, P < 0.001 on day 10 and 14 for L-selectin; P = 0.038 on day 7,
P = 0.001 on day 10, P < 0.001 on day 14 for PSGL-1; P < 0.001 on day 7, 10 and 14 for ADAM17; P < 0.001 on day 7,
10, and 14 for CD11b/CD18). The percentages of the bands and segmented bone marrow (BM) cells in myeloid
neutrophils were higher in the CTX + APS group than in the CTX group on day 7 (P = 0.030) and reached normal
levels on day 10 (P = 0.547) and 14 (P = 0.431) vs. control group. The ability of APS to increase numbers of PMNLs in
peripheral blood after chemotherapy was significantly superior to that of G-CSF 7 days after chemotherapy (P = 0.029
on day 10, P = 0.006 on day 14). Moreover, APS more significantly improved the chemotactic ability of PMNLs among
mature BM granulocytes and peripheral blood neutrophils after chemotherapy than did G-CSF (P < 0.001 on day 7,
P = 0.001 on day 10 and P = 0.005 on day 14).
Conclusions: APS promoted the differentiation and chemotactic ability of BM granulocytes via the L-selectin signaling
pathway.Background
Chemotherapy frequently causes neutropenia, which is a
common and severe adverse effect that interrupts the
treatment. Granulocyte colony-stimulating factor (G-CSF)
is used to promote the proliferation of bone marrow
(BM) hematopoietic cells as a treatment for neutro-
penia. However, apoptosis of hematopoietic progenitor* Correspondence: likai5@medmail.com.cn
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dent after G-CSF stimulation [1]. Moreover, BM does
not have enough niches for the implantation of prolifer-
ated hematopoietic stem/progenitor cells; as a result,
these cells may migrate directly to the peripheral blood
and undergo apoptosis in the liver, spleen, and lung,
causing a transient increase of leukocytes in blood [2].
Furthermore, long-term and excessive administration of
a stimulating factor can lead to increased expression of
matrix metalloproteinase-9 (MMP-9) in CD34+ cells
(naive hematopoietic cells), which dissolves the BM sinus-
oid matrix, thereby allowing proliferated hematopoietic
stem/progenitor cells to move into the peripheral bloodticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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of CD34+ cells are weaker than those of mature cells, so
the presence of these cells in peripheral blood results in
a loss of anti-infection activities. Excessive release of
naive cells can increase the incidence of leukemia [3].
The long-term administration of stimulating factors
may galvanize tumor cell invasion and angiogenesis [4].
In some young patients who undergo first-line chemo-
therapy, active myeloproliferation at 7 days after chemo-
therapy indicates that hematopoietic cells are not
completely suppressed or that they recover (Additional
file 1). Chemotherapy could hinder cell adhesion to the
sinusoid epithelium, prevent release of BM polymorpho-
nuclear leukocytes (PMNLs), and change the morphology
and number of BM sinusoids [5]. Therefore, failure of BM
PMNLs release may also cause neutropenia.
We hypothesized that the interaction between leuko-
cytes and vascular endothelial cells (ECs) when PMNLs
were released from BM was similar to the interactions
involved in the movement of blood PMNLs out of the
capillaries. In such interactions between leukocytes and
ECs, as selectin family member (i.e., leukocyte selectin;
(L-selectin)) [6] is involved in the initial attachment of
circulating leukocytes to the endothelium. P-selectin
glycoprotein ligand-1 (PSGL-1) on adherent neutrophils
acts as a functional ligand for L-selectin [7]. Afterwards,
L-selectin is rapidly shed owing to the action of
ADAM17, a proteolytic enzyme [8]; as a result, leuko-
cytes roll on ECs. Neutrophils firmly adhere to ECs by
subsequently upregulating CD11b/CD18 [9] and move
into sites of inflammation. L-selectin is then crosslinked
with L-selectin on other leukocytes, resulting in in-
creased levels of intracellular calcium, p38MAPK activa-
tion, and expression of mRNAs for TNF-α and IL-8
[10]. These processes result in aggregation of PMNLs at
sites of inflammation and degranulation in response to
inflammation.
L-selectin may also be involved in the adhesion be-
tween granulocytes and sinusoid matrix ECs in the BM.
A continuous increase in the expression of L-selectin
and subsequent movement of mature cells from the BM
stroma into the sinusoids, along with a gradual decrease
in CD34 expression, were observed during the differenti-
ation and maturation of BM blood cells [11]. This
process was also affected by similar ligands of adhesion
molecules and endogenous proteolytic enzymes [12].
Astragalus polysaccharide (APS) has been shown to
significantly increase the numbers of leukocytes, neutro-
phils, and platelets at 4, 7, 10, and 14 days after chemo-
therapy [13]. The present study aims to investigate the
leukogenic effect of APS, to compare its effect of in-
creasing the numbers of mature granulocytes in the
blood with that of G-CSF, and to investigate the under-
lying mechanism of action.Methods
Ethics statement
The experimental protocols were approved by the Ani-
mal Ethical and Welfare Committee of Tianjin Medical
University Cancer Institute and Hospital (No. 058,
date: 2013.1.7) (Additional file 2). The principles of
laboratory animal care and the guidelines of the National
Animal Welfare Law of China were followed when
applicable.
Animal and pharmacological investigation on different
drugs
Male Wistar rats (weighing 180–230 g) obtained from
Charles River Laboratories (China; Certificate No: SCXK
(jing) 2012–0001) were housed in cages (200 rats in 40
cages, five rats per cage) placed in temperature-controlled
rooms. Rats received water and food ad libitum until they
were needed for experimentation. The rats were arbitrarily
grouped: control group, cyclophosphamide (CTX; Jiangsu
Hengrui Medicine Co., Ltd., Jiangsu, China) group, CTX
+APS (Tianjin Cinorch Pharmaceutical Co., Ltd., Tianjin,
China) group, and CTX +G-CSF (Qilu Pharmaceutical
Co., Ltd., Jinan, China) group. Fifty rats were included in
each group. Each group was then arbitrarily divided into
five subgroups (10 rats per subgroup) to provide samples
on different numbers of days after CTX infusion (0, 4, 7,
10, and 14 d). Control animals received 0.4 mL of sterile
phosphate-buffered saline (PBS, Gibco BRL Co.Ltd.,
Grand Island, NY, USA).
Drug doses and schedule of administration were chosen
according to the results of previous studies: (1) intraperi-
toneal injection of 40 mg/kg CTX from day 0 to 1 [14]; (2)
intravenous injection of 100 mg/kg APS from day −2
(2 days before CTX injection) to 11 [15]; and (3) subcuta-
neous injection of 10 μg/kg G-CSF from day 2 to 5 [16].
Blood and BM sampling
The rats were anesthetized by intraperitoneal injection
of chloral hydrate at selected time intervals. Blood sam-
ples were drawn from the abdominal artery and placed
in vacutainer tubes containing EDTA (BD Vacutainer
Systems, Plymouth, UK). The rats were then sacrificed
and their femurs were immediately removed. The epiphy-
ses were cut transversely and the BM cells were flushed
out with Iscove’s modified Dulbecco’s medium containing
584 mg/LL-glutamine (IMDM; HyClone; China) supple-
mented with 10 % heat-inactivated fetal calf serum
(FCS; Yuanhengjinma Biotechnology Kaifa Co., China)
and 100 U/mL lithium heparin. The sternum was re-
moved and extruded for BM smears.
Fractionation of BM cells and isolation of blood PMNLs
Percoll media (GE Healthcare, Bio-Sciences AB) of dif-
ferent densities were prepared as previously described
Zhang et al. Chinese Medicine  (2015) 10:17 Page 3 of 11[17]. A BM cell suspension or whole blood (3 mL) was
gently layered on top of a two-layer discontinuous Percoll
gradient: 1.093 and 1.077 g/mL (72 % and 60 % Percoll)
densities for BM; 1.068 and 1.058 g/mL (51 % and 42 %
Percoll) densities for blood. The tubes were then centri-
fuged at (1000 × g, 20 min, room temperature; Multifuge
1R, Thermo Fisher, USA) to separate the rat BM into three
fractions. The middle-level cell fraction, which contained
PMNLs, was washed twice in 10 mL of PBS (300 × g,
10 min, room temperature) to remove the remaining
Percoll, and erythrocytes contaminating the pellet were
removed using an Optilyse C lysis solution (Beckman
Coulter, France). The PMNLs, separated by Percoll,
were confirmed as BM neutrophil cell lines at various
stages of differentiation by flow cytometry and micros-
copy using oil lens [18]. We used only samples con-
taining >90 % BM PMNLs (bands and segmented
granulocytes) and circulating PMNLs with 95 % cell
viability, as determined by trypan blue staining.
Flow cytometry
Expression of L-selectin, PSGL-1, CD11b/CD18, and
ADAM-17 was assessed using a FACScan flow cyt-
ometer (Beckman Coulter EPICS-XI, USA). BM bands,
segmented cells, and circulating PMNLs were gated in a
forward scatter (cell size) vs. side scatter (granularity)
dot plot. Mature BM granulocyte samples were pretreated
with saturating concentrations of phycoerythrobilin (PE)-
conjugated hamster anti-rat L-selectin monoclonal anti-
body (BD Pharmingen, Catalog No. 551398, USA) with
mouse anti-rat PSGL-1 monoclonal antibody (KPL-
1;Abcam, Catalog No. ab78188, UK), and PE-conjugated
mouse anti-rat CD11b/CD18 monoclonal antibody (BD
Pharmingen, Catalog No. 562105) with rabbit anti-rat
ADAM17 polyclonal antibody (Abcam, Catalog No.
ab2051). Fluorescein isothiocyanate (FITC)-labeled goat
anti-rabbit IgG and goat anti-mouse IgG (ZSGB-BIO,
China) were used as secondary reagents. Negative con-
trols were obtained by omitting monoclonal antibodies.
Class-matched irrelevant PE-labeled hamster IgG2iso-
type control (BD Pharmingen, Catalog No. 553965) and
FITC-labeled goat anti-mouse IgG were used to evaluate
non-specific antibody binding. Data from 100,000
events per sample were acquired. The percentage of
fluorescent cells (%F) was used to quantify L-selectin,
PSGL-1, and ADAM17 expression. The mean fluores-
cence intensity (MFI) was used to quantify CD11b/
CD18 expression after the neutrophils were gated ac-
cording to their characteristic forward and side scatter
properties.
Leukocyte countsand morphological analysis
The total leukocyte count in peripheral blood samples was
obtained using an automated cell counter (MEK-6318 K,Dobio, Japan). Leukocyte differential counts were obtained
for a minimum of 100 cells in blood and BM smears
stained with Giemsa. Granulocytic cells were classified
into immature granulocytes, mature granulocytes (bands
and segmented), eosinophils, and mononuclear cells.
Preparation of zymosan-activated fetal bovine serum (ZAS)
ZAS was prepared as described previously [19]. In brief,
a bovine serum pool with 15 mg/mL of zymosan (Sigma-
Aldrich, Switzerland, USA) was incubated at 37 °C for
60 min. The mixture was subsequently incubated at 56 °C
for 30 min and cooled. Afterwards, the mixture was cen-
trifuged at 1100 × g at 4 °C for 15 min. ZAS was diluted in
a 1:5 Hanks balanced salt solution (without calcium and
magnesium; Gibco BRL Co. Ltd., USA) and filtered
through a 0.22-μm filter (Merck Millipore, Germany).
Measurement of chemotaxis
A micropore membrane was used to assess the chemotac-
tic ability of mature BM granulocytes and blood PMNLs.
Micropore inserts (diameter = 12 mm; pore size = 3 μm;
Corning Incorporated, USA) were coated with collagen
using a 0.1 % solution of calfskin collagen type I (Gibco,
Invitrogen Corporation, Grand Island, USA). The cells
were adjusted to 106/mL in PBS. For the treated group
and the untreated control group, 200 μL of either PMNL
suspension or mature BM granulocytes were added to the
upper chambers. For the treated group, 400 μL of ZAS
was placed in the lower chamber. For the control group,
400 μL of Hanks balanced salt solution was used. All
group samples for the assays were incubated for 90 min at
37 °C in 95 % air and 5 % CO2. The migrated PMNLs and
mature BM granulocytes were counted using a Burker
chamber (Pyser-SGI, UK) at a magnification of 10 × 40.
Results are expressed as the percentage of cells that mi-
grated through the membrane. Each assay was performed
in duplicate.
Statistical analysis
Data are expressed as means ± standard deviation (SD).
All statistical analyses were performed in SPSS 17.0
(SPSS Inc., Chicago, IL, USA). Data were compared
using the Kruskal-Wallis test. Dunn’s multiple contrast
hypothesis test was used to compare each treatment
group mean with each other group mean. The Mann–
Whitney U test was used for unpaired observations. A
P value less than 0.05 was considered significant. The
effect of multiple comparisons was corrected for with
the Bonferroni method.
Results
HE staining of BM
In the control group, a BM section of the humerus
showed abundant erythroid and myeloid cells, normal
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days after CTX chemotherapy, the entire BM cavity was
almost completely filled with adipose cells. Erythroid
and myeloid cells were significantly decreased in number
(this was more evident for myeloid cells), whereas the
structures of microvessels and sinusoids had been
destroyed. On day 4, the proliferation of erythroid and
myeloid cells was higher in the APS and G-CSF treat-
ment groups than in the CTX group, particularly in the
G-CSF group; the latter had capillaries and sinusoids
showing distorted and fuzzy structures, which were not
seen in the APS group (Fig. 1). On day 14, BM prolifer-
ation (erythroid and myeloid cells), was active in all
three CTX treated groups without significant differ-
ence (Additional file 3).Peripheral blood leukocyte and neutrophil count
The proportion of peripheral blood PMNLs among total
white blood cells of the CTX group was not significantly
lower than that in the control group on day 4 after
chemotherapy (P = 0.595). On day 7, the percentage of
PMNLs in the CTX group began to increase. After APS
and G-CSF administration, the proportion of peripheral
blood PMNLs among total white blood cells became
similar to that for the CTX group at each time point,
and a significant increase was observed in the APS
group on day 14 compared with other groups (P = 0.001
vs. control group, P = 0.006 vs. G-CSF group, P = 0.047
vs. CTX group). The percentage of PMNLs in the G-
CSF group was not significantly lower than that in the
CTX group at each time point (P = 0.108 on day 4,
P = 0.053 on day 7, P = 0.068 on day 10, P = 0.207 on
day 14; Fig. 2). On day 4, the white blood cell count
in the G-CSF group was the highest (almost 12 × 109/L)
among all groups, but the percentage of PMNLs among
white blood cells was only 5 %.Fig. 1 HE staining of BM. BM section of the humerus showed abundant er
in the control group. Four days after CTX chemotherapy, the entire BM cav
significantly decreased, with the latter showing a more obvious decrease. Me
day 4, erythroid and myeloid proliferation was higher in the APS and G-CSF tr
control group. The structure of capillaries and sinusoids was distorted and fuzExpression of L-selectin, PSGL-1, ADAM17,
and CD11b/CD18
On day 4, the positive expression rate (F%) of L-selectin
in mature BM granulocytes in the CTX group was 59.10
± 8.45 %, which was higher than that in the control
group (P < 0.001). F% decreased on days 7, 10, and 14. A
significant difference was observed on days 7 and 14 (P
< 0.001 on day 7 and P = 0.043 on day 14vs. control
group), whereas F% in the APS group gradually in-
creased from day 4 to 14 after chemotherapy and
reached 49.53 ± 8.92 % on day 14. F% of L-selectin in the
G-CSF group was the highest on day 4 (48.60 ± 3.08 %)
and gradually decreased to 28.67 ± 9.10 % on day 14. In
contrast, F% of L-selectin in the APS group was higher
than that of the G-CSF group after 7 days (P = 0.005 on
day 7, P < 0.001 on day 10, P < 0.001 on day 14). On day
4, F% of L-selectin in the two treatment groups was sig-
nificantly lower than that in the CTX group (P < 0.001
vs. APS group, P = 0.001 vs. G-CSF group), but signifi-
cantly higher than that in the CTX group after 7 days
(P < 0.001 on day 7, P < 0.001 on day 10, P < 0.001 on
day 14 vs. APS group; P < 0.001 on day 7, P = 0.001 on
day 10, P = 0.003 on day 14 vs. G-CSF group).
F% of PSGL-1 in the mature BM granulocytes after
CTX treatment decreased gradually on days 4–14. No
significant change in F% was observed in the APS group
on days 4 and 7 (P = 0.776 on day 4, P = 0.788 on day
7vs. control group); however, F% gradually increased
from day 10 to day 14 (23.25 ± 8.78 % and 28.33 ±
6.63 %, respectively; P < 0.001 on day 10, P < 0.001 on
day 14vs. control group). On day 7, F% of PSGL-1 in the
APS group was significantly higher than that in the CTX
group (P < 0.001); however, no significant difference in
F% was observed between the G-CSF and CTX groups
before day 14 (P = 0.415 on day 4, P = 0.802 on day 7,
P = 0.889 on day 10). F% gradually decreased after G-
CSF was injected, and the lowest value was reached onythroid and myeloid cells, normal differentiation, and visible capillaries
ity was almost filled with fat cells. Erythroid and myeloid cells were
anwhile, the structures of microvessels and sinusoids were destroyed. At
eatment groups, especially in the G-CSF group, compared with the
zy in the G-CSF group, but clear in the APS group
Fig. 2 Peripheral blood leukocyte and neutrophil count. Total leukocyte count of the peripheral blood samples was obtained using an
automated cell counter. Leukocyte differential count was carried out on a minimum of 100 cells. a Peripheral blood leukocyte and neutrophil
count after drug administration at different time points. In the G-CSF group, the number of total white blood cells significantly increased on day
4 and then gradually decreased thereafter. In the APS group, total leukocyte count gradually increased. No statistical difference was observed
between the APS and G-CSF groups after 7 days (P > 0.05). b With APS and G-CSF administration, the proportion of peripheral blood PMNLs in
total white blood cells started to increase, and a significant increase was observed in the APS group on day 14 (vs. the CTX group and G-CSF
groups, P < 0.05). However, the percentage of PMNLs in total white blood cells in the G-CSF group was slightly lower than that of the CTX group
at each time point (P > 0.05). Data were expressed as means ± SD. Comparison of CTX + APS and CTX + G-CSF groups showed a significant
difference (**:P < 0.01, *: P < 0.05). Comparison of CTX + APS group and CTX group showed a significant difference (^ ^: P < 0.01, ^: P < 0.05)
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PSGL-1 in the APS group was higher than that in the
G-CSF group (P = 0.038 on day 7, P = 0.001 on day 10,
P < 0.001 on day 14; Fig. 3).
F% of ADAM17 in mature BM granulocytes in the
CTX group on days 4 to 14 was insignificantly lower
than that in the control group (P = 0.176 on day 4, P =
0.204 on day 7, P = 0.101 on day 10, P = 0.368 on day
14). At each time point, the APS group showed higher
F% than did the control, CTX, and G-CSF groups (P =
0.007 on day 4, P < 0.001 on day 7, P < 0.001 on day 10,
P < 0.001 on day 14 vs. control group; P = 0.003 on day
4, P < 0.001 on day 7, P < 0.001 on day 10, P < 0.001 onday 14 vs. CTX group; P = 0.006 on day 4, P < 0.001 on
day 7, P < 0.001 on day 10, P < 0.001 on day 14 vs. G-
CSF group), with the maximum F% of 83.52 ± 12.36 %
obtained 14 days after chemotherapy. F% of ADAM17 in
the G-CSF group did not change significantly at each
time point (P = 0.892 on day 4, P = 0.574 on day 7, P =
0.727 on day 10, P = 0.822 on day 14 vs. control group;
P = 0.425 on day 4, P = 0.168 on day 7, P = 0.062 on day
10, P = 0.916 on day 14vs. CTX group; Fig. 3).
MFI of CD11b/CD18 on mature BM granulocytes sig-
nificantly decreased after CTX treatment, and was fur-
ther reduced by 50 % on days 10 and 14. The minimum
MFI (15.98 ± 8.16) in the APS group was obtained on
Fig. 3 (See legend on next page.)
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Fig. 3 Expression of L-selectin, PSGL-1, ADAM17 and CD11b/CD18. a Light microscopy of the gated cells obtained after sorting the corresponding
fractions (original magnification, 600 ×). b %F of L-selectin expression on the cell surface of mature BM granulocytes in each group. c %F of
PSGL-1 expression on the cell surface of mature BM granulocytes in each group. d %F of ADAM-17 expression on the cell surface of mature BM
granulocytes in each group. e MFI of CD11b/CD18 expression on the cell surface of mature BM granulocytes in each group. f and g Flow cytometry
analysis on mature BM granulocytes after density gradient centrifugation: forward scatter (FS) vs. side scatter (SS) dot plot, and scatter plot of protein
expression in CTX and APS groups. Data were expressed as means ± SD. Comparison of CTX + APS group and CTX + G-CSF group showed a significant
difference (**:P < 0.01, *: P < 0.05). Comparison of CTX + APS group and CTX group showed a significant difference (^ ^: P < 0.01, ^: P < 0.05)
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and 14 (P = 0.154 on day 7, P = 0.169 on day 10, P = 0.052
on day 14vs. control group, P = 0.028 on day 7, P < 0.001
on day 10, P < 0.001 on day 14vs. CTX group). The max-
imum MFI (29.56 ± 5.12) was obtained in the G-CSF
group on day 4 (P = 0.136vs. control group). MFI in the
G-CSF group was significantly decreased on days 7, 10,
and 14 compared with that in the APS group (P < 0.001
on day 7, P < 0.001 on day 10, P < 0.001 on day 14). MFI
in the G-CSF group was lower than that in the control
group (P > 0.05) but insignificantly higher than that in the
CTX group (P > 0.05) (Fig. 3).
Differentiation of BM granulocytes
Using the BM smears collected from the sternum, we
counted the proportion of bands and segmented cells in
the total number of neutrophils under a microscope to
identify the degree of BM neutrophil differentiation. The
lowest percentage of BM bands and segmented cells in
the CTX group was observed on days 4 and 7 (24.70 ±
5.77 % and 19.45 ± 7.23 %, respectively), but this propor-
tion subsequently increased on days 10 and 14 (P = 0.032
on day 10, P = 0.127 on day 14vs. control group). After
day 4, the percentages in the APS and G-CSF groups grad-
ually increased as well, while on day 7, the percentage of
BM bands and segmented cells was higher than that in
the CTX group (P = 0.030 vs. APS group, P = 0.016 vs.
G-CSF group), although this result was not statistically
different from the CTX group results on days 10 and 14.
The percentage in the APS group significantly increased
and reached normal levels on days 10 and 14 (P = 0.547
on day 10 and P = 0.431 on day 14vs. control group; P =
0.015 on day 10 and P = 0.007 on day 14vs. G-CSF group;
Fig. 4).
Chemotactic ability of mature BM granulocytes and
peripheral blood PMNLs
The chemotactic ability of mature BM granulocytes and
peripheral blood PMNLs in the CTX group was signifi-
cantly decreased compared with that of cells in the
control group at each time point. In the CTX group,
the minimum percentage value was obtained on day 4
(P < 0.001vs. control group). The value for the CTX
group was approximately 50 % of that for the control
group on day 14. In the APS group, the minimumpercentage value was obtained on day 4, before grad-
ually increased on days 7, 10, and 14. The chemotactic
ability of mature BM granulocytes and peripheral blood
PMNLs was higher in the APS group than in the CTX
group (P < 0.001 on days 7, 10 and 14) and the G-CSF
group (P < 0.001 on day 7, P = 0.001 on day 10 and P =
0.005 on day 14), particularly on days 10 and 14 after
chemotherapy. In the CTX group, the maximum value
was obtained on day 4, but this result was not significantly
different from that in the control group. A decrease was
observed on days 7, 10, and 14, but the decrease was not
significant. On days 10 and 14, the chemotactic ability in
the G-CSF group was lower than that in the control and
APS groups (P = 0.028 on day 10 and P = 0.017 on day 14
vs. control group; P = 0.001 on day 10 and P = 0.005 on
day 14 vs. APS group), and mature BM granulocytes and
peripheral blood PMNLs in the APS group showed signifi-
cant improvements in such capabilities after 7 days rela-
tive to those in the CTX group (Fig. 5).
Discussion
Design of treatment protocols
The administration of 10 μg/kg G-CSF from day 2 to
day 5 after chemotherapy based on a previous report
[16] and the results of our pilot experiment could enable
the maximal stimulation of proliferation of neutrophils
to be achieved, leading to severe leakage from vessels,
edema, and even the death of several rats [15]. APS was
given in different ways in our pilot studies to obtain the
maximal effect; ‘pre-chemotherapeutic administration’
and maintenance for 11 days after chemotherapy were
determined to be the best protocols to increase neutro-
phils. The most suitable protocols for the two drugs
were chosen to compare their maximal effects and to
ensure safety in animals.
Effects on adhesion/release-related protein expression in
mature BM granulocytes
Frenette and Weiss [20] confirmed that PMNLs express-
ing L-selectin can be preferentially released from the
BM into the peripheral blood. ADAM17 is a major pro-
teolytic enzyme that hydrolyzes the extracellular and
juxtamembrane region of L-selectin [21]. Our results
showed that CTX could reduce expression of L-selectin,
PSGL-1, CD11b/CD18, and ADAM17 from day 7–14 by
Fig. 4 Differentiation of BM granulocytes. BM smears collected from the sternum at different time points were used. We determined the
proportion of BM bands and segmented cells in the total number of neutrophils, and used a microscope to identify the degree of
differentiation of BM neutrophils. a BM smears observed under oil microscopy (600×) showed granulocyte differentiation on day 14.
b Leukocyte differential counts were carried out on a minimum of 500 cells on BM smears stained with Giemsa. Cells of the granulocytic
lineage were classified as immature granulocytes (myeloblasts, promyelocytes, myelocytes, and metamyelocytes), mature granulocytes
(bands and segmented), eosinophils, and mononuclear cells. Data were expressed as means ± SD. Comparison of CTX + APS group and
CTX + G-CSF group showed a significant difference (**:P < 0.01, *: P < 0.05). Comparison of CTX + APS group and CTX group showed a
significant difference (^ ^: P < 0.01, ^:P < 0.05)
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granulocytes and sinusoidal endothelial cells, and smooth
PMNL release. G-CSF could reduce this interference to
a certain extent, but the effect was short lived; con-
trastingly, APS could significantly increase the expres-
sion levels of key proteins involved in granulocyte
adhesion and release for a longer time (maximum of
7 days to 14 days). To our knowledge, our study is the
first to elucidate that APS could relieve chemotherapy-
induced impairment on key factors related to adhesion
and release of PMNLs.Effects on microvessel and sinusoid structures in BM
Chemotherapeutic agents could significantly reduce
hematopoietic islets, resulting in severe suppression in
bone marrow hematopoiesis [22]. However, the reasons
for chemotherapy-induced anemia should be more than
just inhibition of proliferation of hematopoietic cells
alone. Our findings revealed that CTX resulted in a fuzzy
structure of microvessels and sinusoids in BM 4 days after
chemotherapy. This damage in a hematopoietic micro-
environment could impair the environment for prolifera-
tion and differentiation of hematopoietic cells, and also
Fig. 5 Chemotactic ability of mature BM granulocytes and peripheral blood PMNLs. A micropore membrane was used to assess the chemotactic
ability of mature BM granulocytes (a) and blood PMNLs (b). The chemotactic ability of mature BM granulocytes and peripheral blood PMNLs
significantly decreased at each time point. In the CTX group, the minimum value was obtained on day 4 (P < 0.001 vs. control group). At each
time point thereafter, the values were significantly lower than those of the other treatment groups, and the value of the CTX group was only
50 % of control group on day 14. In the APS group, the minimum value obtained on day 4, before gradually increasing on days 7, 10, and 14.
The chemotactic ability of both mature BM granulocytes and peripheral blood PMNLs of the APS group were higher than those of the CTX
group (P < 0.01), and the G-CSF group, especially 10 and 14 days after chemotherapy. The maximum value obtained in the CTX group on day 4
was not significantly different with that of the control group. The decrease in values observed on day 7, 10, and 14 was not significant. On day
10 and 14, the chemotactic ability in the G-CSF group was lower than that of the control and APS groups (P < 0.05). Compared with the CTX
group, the chemotactic ability of mature BM granulocytes and peripheral blood PMNLs in APS group improved significantly after 7 days. Data
were expressed as means ± SD. Comparison of CTX + APS group and CTX + G-CSF group showed a significant difference (**:P < 0.01, *: P < 0.05).
Comparison of CTX + APS group and CTX group showed a significant difference (^ ^: P < 0.01, ^: P < 0.05)
Zhang et al. Chinese Medicine  (2015) 10:17 Page 9 of 11interfere with the adhesion and release of granulocytes. G-
CSF could not restore the structure of microvessels and si-
nusoidal ECs. After APS treatment, the structures of BM
microvessels and sinusoids became clear and organized,
and adhesion and release of mature BM granulocytes were
promoted. Given the enhancement of the immunocyto-
toxic function of APS against malignancies [23], we be-
lieve that its ‘protection’ of the bone marrow stroma could
hardly protect tumors from chemotherapy.
Effects on the differentiation and release of granulocytes
in BM
The BM section of the humerus showed that the BM cav-
ity was filled with adipose cells 4 days after chemotherapyand erythroid and myeloid cell counts significantly de-
creased. Xue et al. [24, 25] found a severe defect in BM by
loosing hematopoietic cells in VEGF tumor-bearing mice
probably due to possibility for VEGF to mobilize BM
hematopoietic stem cells to peripheral tissues and organs.
After APS and G-CSF administration, the proliferation of
myeloid cells was observed. In the G-CSF group, the ratio
of mature BM granulocytes to the total neutrophils was
lower than that of the CTX group, suggesting that G-
CSF remarkably stimulated the proliferation of naive
hematopoietic cells [26]. Only 5 % of PMNLs were
found 4 days after chemotherapy, when the highest
levels of WBC were found in G-CSF group, suggesting
that G-CSF prompts non-PMNLs releasing from bone
Zhang et al. Chinese Medicine  (2015) 10:17 Page 10 of 11marrow to peripheral blood. Janowska-Wieczorek et al.
[27] demonstrated that G-CSF-induced the release of
gelatinase B, which has a major function in the migra-
tion of BM early-stage myeloid cells into the blood. The
total white blood cells reached normal level as induced
by APS at day 14, while the proportion of mature BM
granulocytes to the total neutrophils reached normal
levels at day 10 and 14 in the APS group. Above results
confirmed that APS promoted myeloid differentiation
and maturation, and reduced mobilization of naïve BM
hematopoietic cells to peripheral tissues, which yield a
question that ought to be explored and might be the
possibility for APS to restore BM hematopoiesis in pa-
tient with advanced cancer. APS augmented the expres-
sion of signalling molecules, releasing PMNLs after
chemotherapy. This result is consistent with what is ob-
served in leukemia cells with lower L-selectin expression,
showing impaired transendothelial migration in vitro [28].Effects on the chemotactic ability
To assess the chemotactic ability of PMNLs, we measured
the ability of mature BM granulocytes and circulating
PMNLs to pass through collagen-coated membranes to
ZAS. The chemotactic ability of BM and PMNLs in the
CTX group markedly decreased to 50 % of that in the
control group at 14 d after chemotherapy. G-CSF could
increase the chemotactic ability of PMNLs until day 7
after chemotherapy, but APS consistently increased this
capability of PMNLs more effectively than G-CSF did.
This result mightbe attributable to the upregulation of key
proteins, such as TNF-α and IL-8, in the L-selectin signal-
ling pathway in PNMLs by APS.
The activation of human granulocytes via cross-linking
between L-selectin and its antibody can increase intracel-
lular Ca2+ concentration [29], production and phosphoryl-
ation of superoxides [30], and activation of key signalling
proteins [31]. Cross-linking of L-selectin and its ligand
as sulphated galactocerebroside increased the expres-
sion of TNF-α and IL-8 [10], causing granulocytes to
penetrate the layer of human umbilical vein ECs. The
inability of G-CSF to increase the chemotactic ability
was probably due to its inability to restore the key pro-
teins in the L-selectin signalling pathway. High expres-
sion of CD11b/CD18 was observed after the activation
of granulocytes by cross-linking of L-selectin, which is
closely related to the chemotactic ability of granulocytes
in addition to mediating the stable adhesion of granulo-
cytes [30].Conclusions
APS promoted differentiation and chemotactic ability
of BM granulocytes, involving the L-selectin signalling
pathway.Additional files
Additional file 1: HE staining of BM of a lung cancer patient
(45 years old, male, 7 days after his 3rd cycle of chemotherapy)
shows active myeloproliferation.
Additional file 2: The Certification of the approval of The
Laboratory Animal Ethic Committee.
Additional file 3: HE staining of BM. BM section of the humerus
showed abundant erythroid and myeloid cells, normal differentiation, and
visible capillaries in the control group. Four days after CTX chemotherapy,
the entire BM cavity was almost filled with fat cells. Erythroid and
myeloid cells were significantly decreased, with the latter showing a
more obvious decrease. Meanwhile, the structures of microvessels and
sinusoids were destroyed. At day 4, erythroid and myeloid proliferation
was higher in the APS and G-CSF treatment groups, especially in the
G-CSF group, compared with the control group. The structure of
capillaries and sinusoids was distorted and fuzzy in the G-CSF group, but
clear in the APS group. On day 14, BM proliferation was active in all three
CTX treated groups without significant difference.
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